Here are four things to know:
1. VolitionRX’s system works by collecting a blood sample from a patient.
2. The sample is analyzed for cancer specific nucleosome patterns and structures.
3. The company has been awarded numerous patents for the detection of nucleosomes.
4. VolitionRX has been approved to start selling the product in Europe.
More articles on GI/endoscopy:
Innovative colorectal cancer screening methods for remote areas
FDA clears 5 GI/endoscopy devices in December
US Endoscopy acquires Bracco Diagnostics’ GI business unit
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.